Moneycontrol PRO
HomeNewsBusinessCompaniesOrchid Chemicals gets USFDA nod for anti-depression capsule

Orchid Chemicals gets USFDA nod for anti-depression capsule

Drug firm Orchid Chemicals & Pharmaceuticals today said it has received final approval from the US health regulator for its generic Venlafaxine capsules, used in the treatment of depression.

July 14, 2011 / 15:12 IST
     
     
    26 Aug, 2025 12:21
    Volume
    Todays L/H
    More

    Drug firm Orchid Chemicals & Pharmaceuticals today said it has received final approval from the US health regulator for its generic Venlafaxine capsules, used in the treatment of depression.


    The final approval from the United States Food and Drug Administration (USFDA) is for its abbreviated new drug application (ANDA) for Venlafaxine extended release capsules in strengths of 37.5 mg, 75 mg and 150 mg, Orchid Chemicals & Pharmaceuticals said in a filing to the Bombay Stock Exchange (BSE).

    Also read: Dr Reddy's gets USFDA ok for deep vein thrombosis injection


    Venlafaxine extended release capsules are used for treating major depressive disorders (MDD) and falls under the central nervous system (CNS) category.


    Venlafaxine was introduced by drug-maker Wyeth in 1993 under the brand name Effexor.


    Shares of Orchid Chemicals & Pharmaceuticals were being quoted at Rs 254 apiece in afternoon trade on the BSE today, up 0.89% from their previous close.

    first published: Jul 14, 2011 02:19 pm

    Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

    Subscribe to Tech Newsletters

    • On Saturdays

      Find the best of Al News in one place, specially curated for you every weekend.

    • Daily-Weekdays

      Stay on top of the latest tech trends and biggest startup news.

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347